BR112019001099A2 - usos de vesículas extracelulares compreendendo uma proteína de fusão tendo capacidade de ligação a fc - Google Patents
usos de vesículas extracelulares compreendendo uma proteína de fusão tendo capacidade de ligação a fcInfo
- Publication number
- BR112019001099A2 BR112019001099A2 BR112019001099A BR112019001099A BR112019001099A2 BR 112019001099 A2 BR112019001099 A2 BR 112019001099A2 BR 112019001099 A BR112019001099 A BR 112019001099A BR 112019001099 A BR112019001099 A BR 112019001099A BR 112019001099 A2 BR112019001099 A2 BR 112019001099A2
- Authority
- BR
- Brazil
- Prior art keywords
- fusion protein
- binding capacity
- extracellular vesicles
- ves
- coated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
- A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
Abstract
a presente invenção se refere a terapêutica de vesícula extracelular (ve), em que as ves são revestidas com proteínas contendo domínios fc (tais como anticorpos) para i.a. direcionamento e aplicações terapêuticas. o revestimento de ves é obtido através da manipulação de proteínas inventivas de polipeptídeos de ve. a presente invenção se refere assim a métodos para revestimento de ves, ves per se, bem como composições farmacêuticas e aplicações médicas de tais ves revestidas com proteínas contendo fc.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1612643.5A GB2552473A (en) | 2016-07-21 | 2016-07-21 | Surface decoration of extracellular vesicles |
PCT/EP2017/068476 WO2018015535A1 (en) | 2016-07-21 | 2017-07-21 | Extracellular vesicle comprising a fusion protein having fc binding capacity |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019001099A2 true BR112019001099A2 (pt) | 2019-06-25 |
Family
ID=56894359
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019001108A BR112019001108A2 (pt) | 2016-07-21 | 2017-07-21 | usos de vesículas extracelulares compreendendo uma proteína de fusão tendo capacidade de ligação a fc |
BR112019001099A BR112019001099A2 (pt) | 2016-07-21 | 2017-07-21 | usos de vesículas extracelulares compreendendo uma proteína de fusão tendo capacidade de ligação a fc |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019001108A BR112019001108A2 (pt) | 2016-07-21 | 2017-07-21 | usos de vesículas extracelulares compreendendo uma proteína de fusão tendo capacidade de ligação a fc |
Country Status (12)
Country | Link |
---|---|
US (3) | US11236143B2 (pt) |
EP (3) | EP3487528B1 (pt) |
JP (4) | JP7140743B2 (pt) |
KR (2) | KR102636776B1 (pt) |
CN (2) | CN109689098A (pt) |
AU (2) | AU2017299214A1 (pt) |
BR (2) | BR112019001108A2 (pt) |
CA (2) | CA3031186A1 (pt) |
GB (1) | GB2552473A (pt) |
MX (2) | MX2019000863A (pt) |
SG (4) | SG10202100598RA (pt) |
WO (2) | WO2018015535A1 (pt) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2618821A4 (en) | 2010-09-24 | 2014-08-13 | Brigham & Womens Hospital | NANOSTRUCTURED GELS FOR CONTROLLED RELEASE OF CAPSUED MEDIUM |
GB2552473A (en) * | 2016-07-21 | 2018-01-31 | Evox Therapeutics Ltd | Surface decoration of extracellular vesicles |
US11020410B2 (en) | 2017-02-03 | 2021-06-01 | The Brigham And Women's Hospital, Inc. | Self-assembled gels formed with anti-retroviral drugs, prodrugs thereof, and pharmaceutical uses thereof |
AU2018316166A1 (en) | 2017-08-07 | 2020-02-06 | The Regents Of The University Of California | Platform for generating safe cell therapeutics |
GB201717446D0 (en) * | 2017-10-24 | 2017-12-06 | Evox Therapeutics Ltd | Affinity purification of engineering extracellular vesicles |
GB201804291D0 (en) * | 2018-03-16 | 2018-05-02 | Evox Therapeutics Ltd | Cell-mediated exosome delivery |
US20190307885A1 (en) | 2018-04-04 | 2019-10-10 | Alivio Therapeutics, Inc. | Self-assembled gels for controlled delivery of biologics and methods of making thereof |
CN110655585A (zh) * | 2018-06-28 | 2020-01-07 | 中央研究院 | 合成多肽及其用途 |
US20210300992A1 (en) * | 2018-07-20 | 2021-09-30 | The Board Of Trustees Of The Leland Stanford Junior University | Soluble Polypeptides and Methods of Using Same for Inhibiting Leukemia Inhibitory Factor Activity |
KR20210045409A (ko) | 2018-08-14 | 2021-04-26 | 에버사이트 게엠베하 | 표적 특이적 세포외 소포 |
CN108998402B (zh) * | 2018-08-28 | 2020-05-29 | 江南大学 | 一种重组枯草芽孢杆菌及其构建方法与应用 |
WO2020051507A1 (en) | 2018-09-06 | 2020-03-12 | The Broad Institute, Inc. | Nucleic acid assemblies for use in targeted delivery |
CA3116329A1 (en) * | 2018-10-19 | 2020-04-23 | Ohio State Innovation Foundation | Nanocarriers for lung inflammation therapy |
SG11202103756XA (en) * | 2018-10-19 | 2021-05-28 | Ohio State Innovation Foundation | Extracellular vesicles for targeted therapies against myeloid-derived suppressor cells |
JP2022512988A (ja) * | 2018-11-16 | 2022-02-07 | エヴォックス・セラピューティクス・リミテッド | 尿素サイクルタンパク質および核酸を補充するための細胞外小胞 |
US20230295312A1 (en) * | 2018-12-27 | 2023-09-21 | Akeso Biopharma, Inc | Antibody against human il-4ra and use thereof |
CA3128386A1 (en) * | 2019-02-04 | 2020-08-13 | Codiak Biosciences, Inc. | Membrane protein scaffolds for exosome engineering |
CN113924126A (zh) * | 2019-05-06 | 2022-01-11 | 托马斯·马尔科姆 | 为癌症肿瘤定制的低免疫纳米囊泡递送系统 |
CA3143327A1 (en) * | 2019-06-13 | 2020-12-17 | J. Keith Joung | Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells |
WO2020249757A1 (en) * | 2019-06-14 | 2020-12-17 | Philogen S.P.A | Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha |
AU2020298314A1 (en) * | 2019-06-21 | 2022-02-03 | Entelexo Biotherapeutics Inc. | Platforms, compositions, and methods for therapeutics delivery |
JP2022543851A (ja) * | 2019-08-06 | 2022-10-14 | オハイオ・ステイト・イノベーション・ファウンデーション | 治療用細胞外小胞 |
CN114173807B (zh) * | 2019-09-02 | 2024-03-19 | 庆北大学校产学协力团 | 包含il-2表面表达-细胞外囊泡作为活性成分的用于预防或治疗癌症的组合物 |
CN112941028A (zh) * | 2019-12-09 | 2021-06-11 | 上海细胞治疗集团有限公司 | 纳米抗体基因修饰的间充质干细胞及其制备方法与应用 |
EP4099984A4 (en) | 2020-02-05 | 2024-05-01 | Diadem Biotherapeutics Inc | ARTIFICIAL SYNAPSES |
US20230149319A1 (en) * | 2020-04-13 | 2023-05-18 | City Of Hope | Cell-receptor targeted exosomes |
CN111544453B (zh) * | 2020-04-27 | 2021-01-22 | 高连如 | 一种包含三种血管再生属性的混合干细胞注射液及其制备方法 |
CN111560352B (zh) * | 2020-06-02 | 2023-03-24 | 新疆农业大学 | 一种病毒样囊泡及其制备方法和应用 |
CN111905105B (zh) * | 2020-07-02 | 2023-05-05 | 华南师范大学 | 一种用于癌症靶向治疗的蛋白类纳米药物及其制备方法 |
CN112111513A (zh) * | 2020-07-17 | 2020-12-22 | 深圳市第二人民医院 | 基于外泌体平台的新冠病毒疫苗制备方法 |
CN113967254B (zh) * | 2020-08-04 | 2022-08-12 | 华南理工大学 | 用于多特异性抗体递送的细胞膜包覆型纳米适配子及应用 |
JP2023536665A (ja) * | 2020-08-05 | 2023-08-28 | オハイオ・ステイト・イノベーション・ファウンデーション | アダプターポリペプチドおよびその使用方法 |
CN112285195B (zh) * | 2020-10-27 | 2021-08-10 | 江南大学 | 一种牛奶外泌体的特征性糖蛋白标志物和牛奶外泌体的特征性标志物分离方法 |
WO2022149779A1 (ko) * | 2021-01-11 | 2022-07-14 | 주식회사 엑소코바이오 | 과발현된 Fc 수용체 또는 이의 일부를 포함하는 엑소좀 및 이의 제조방법 |
KR102252325B1 (ko) * | 2021-01-14 | 2021-05-14 | 이장호 | 태아 유래 태초 면역글로불린을 포함하는 세포외소포의 제조방법 |
WO2022158836A1 (ko) * | 2021-01-21 | 2022-07-28 | 주식회사 엑소코바이오 | 목적 단백질 또는 펩타이드가 융합가능한 Fc 수용체 또는 이의 일부를 포함하는 재조합 엑소좀 및 이의 용도 |
WO2022219058A1 (en) * | 2021-04-14 | 2022-10-20 | Anjarium Biosciences Ag | Fc-derived polypeptides |
WO2022219075A2 (en) * | 2021-04-14 | 2022-10-20 | Anjarium Biosciences Ag | Peptides, nanovesicles, and uses thereof for drug delivery |
GB202107182D0 (en) * | 2021-05-19 | 2021-06-30 | Evox Therapeutics Ltd | Nanoparticle delivery system for production of engineered extracellular vesicles |
CN113599516B (zh) * | 2021-08-16 | 2022-02-18 | 上海蒙彼利生物技术有限公司 | 制备外泌体方法及其药物组合物在组织修复中的应用 |
KR102577502B1 (ko) * | 2021-09-08 | 2023-09-13 | 주식회사 꿈랩 | 생체분자의 안정적 발현 및 전달을 위한 플라스미드 플랫폼 |
CN113897387B (zh) * | 2021-10-09 | 2023-09-05 | 深圳市汉科生命工程有限公司 | 一种具有促进毛发再生功能的基因重组msc及其外泌体样纳米材料的制备方法和应用 |
CN114236113B (zh) * | 2021-12-21 | 2023-07-21 | 南京农业大学 | 一种2,4-滴的即用型免疫传感器 |
WO2023133425A1 (en) * | 2022-01-04 | 2023-07-13 | The Broad Institute, Inc. | Compositions and methods for delivering cargo to a target cell |
WO2023196586A1 (en) * | 2022-04-07 | 2023-10-12 | The Regents Of The University Of Michigan | Methods and devices for screening extracellular vesicles |
CN117802045A (zh) * | 2022-09-30 | 2024-04-02 | 北京恩康医药有限公司 | 一种工程化细胞外囊泡的构建及其应用 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4090299A (en) * | 1998-05-20 | 1999-12-06 | Sdg, Inc. | Liposomal delivery complex |
US20040241176A1 (en) * | 2000-04-27 | 2004-12-02 | Ap Cells. Inc. | Method of producing membrane vesicles |
US20070128117A1 (en) * | 2003-02-04 | 2007-06-07 | Bracco International B.V. | Ultrasound contrast agents and process for the preparation thereof |
JP2007295929A (ja) * | 2006-04-05 | 2007-11-15 | Geno Membrane:Kk | イヌBsep遺伝子 |
AU2008291604B2 (en) * | 2007-08-30 | 2013-12-05 | Akshaya Bio Inc. | Antigenic compositions and use of same in the targeted delivery of nucleic acids |
US8282930B2 (en) * | 2007-09-24 | 2012-10-09 | The University Of Queensland | Molecular delivery vehicle |
EP3569254B1 (en) | 2009-04-17 | 2022-07-20 | Oxford University Innovation Limited | Composition for delivery of genetic material |
PT2654780T (pt) * | 2010-12-23 | 2017-04-06 | Janssen Biotech Inc | Mutantes ativos de fc de anticorpos resistentes a proteases |
EP2675474B1 (en) | 2011-02-15 | 2019-01-16 | Vaxiion Therapeutics, LLC | Therapeutic compositions and methods for antibody and fc-containing targeting molecule-based targeted delivery of bioactive molecules by bacterial minicells |
GB201121069D0 (en) | 2011-12-07 | 2012-01-18 | Isis Innovation | Delivery system |
GB201121070D0 (en) | 2011-12-07 | 2012-01-18 | Isis Innovation | composition for delivery of biotherapeutics |
JP6542197B2 (ja) | 2013-04-12 | 2019-07-10 | エヴォックス・セラピューティクス・リミテッド | 治療的送達小胞 |
WO2015002956A1 (en) | 2013-07-01 | 2015-01-08 | Ohio State Innovation Foundation | Exosome delivery system |
US10538570B2 (en) * | 2013-09-30 | 2020-01-21 | Northwestern University | Targeted and modular exosome loading system |
EP3057662A4 (en) * | 2013-10-17 | 2017-03-29 | Children's Hospital Los Angeles | Antibody dependent exosome therapy |
WO2015143113A1 (en) * | 2014-03-20 | 2015-09-24 | Barb Ariel Cohen | Preparations of derived extracellular vesicles, assays, and methods to modify therapeutic outcomes using such preparations |
GB2552473A (en) * | 2016-07-21 | 2018-01-31 | Evox Therapeutics Ltd | Surface decoration of extracellular vesicles |
-
2016
- 2016-07-21 GB GB1612643.5A patent/GB2552473A/en not_active Withdrawn
-
2017
- 2017-07-21 BR BR112019001108A patent/BR112019001108A2/pt not_active IP Right Cessation
- 2017-07-21 US US16/319,061 patent/US11236143B2/en active Active
- 2017-07-21 US US16/319,087 patent/US20230181757A1/en not_active Abandoned
- 2017-07-21 MX MX2019000863A patent/MX2019000863A/es unknown
- 2017-07-21 EP EP17749395.4A patent/EP3487528B1/en active Active
- 2017-07-21 BR BR112019001099A patent/BR112019001099A2/pt not_active IP Right Cessation
- 2017-07-21 CA CA3031186A patent/CA3031186A1/en active Pending
- 2017-07-21 SG SG10202100598RA patent/SG10202100598RA/en unknown
- 2017-07-21 EP EP17749397.0A patent/EP3487529A1/en active Pending
- 2017-07-21 KR KR1020197005096A patent/KR102636776B1/ko active IP Right Grant
- 2017-07-21 WO PCT/EP2017/068476 patent/WO2018015535A1/en unknown
- 2017-07-21 MX MX2019000861A patent/MX2019000861A/es unknown
- 2017-07-21 CA CA3031183A patent/CA3031183A1/en active Pending
- 2017-07-21 KR KR1020197005093A patent/KR20190032479A/ko active Search and Examination
- 2017-07-21 WO PCT/EP2017/068486 patent/WO2018015539A1/en unknown
- 2017-07-21 AU AU2017299214A patent/AU2017299214A1/en not_active Abandoned
- 2017-07-21 CN CN201780045183.0A patent/CN109689098A/zh active Pending
- 2017-07-21 CN CN201780045139.XA patent/CN109689097B/zh active Active
- 2017-07-21 SG SG11201811152YA patent/SG11201811152YA/en unknown
- 2017-07-21 SG SG10202100597TA patent/SG10202100597TA/en unknown
- 2017-07-21 AU AU2017300035A patent/AU2017300035A1/en not_active Abandoned
- 2017-07-21 JP JP2019502253A patent/JP7140743B2/ja active Active
- 2017-07-21 SG SG11201811151PA patent/SG11201811151PA/en unknown
- 2017-07-21 JP JP2019502697A patent/JP7254016B2/ja active Active
- 2017-07-21 EP EP23192812.8A patent/EP4299137A3/en active Pending
-
2021
- 2021-12-15 US US17/551,582 patent/US20220098267A1/en active Pending
-
2022
- 2022-05-24 JP JP2022084613A patent/JP2022117998A/ja active Pending
- 2022-12-01 JP JP2022192884A patent/JP2023026440A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019001099A2 (pt) | usos de vesículas extracelulares compreendendo uma proteína de fusão tendo capacidade de ligação a fc | |
CL2022000036A1 (es) | Polipéptidos modificados y usos de los mismos (divisional de solicitud no. 201900261) | |
CO2018002450A2 (es) | Proteínas de fusión de gitrl y usos de las mismas | |
CL2022000300A1 (es) | Muteínas de interleucina 21 y sus usos para tratar tumores sólidos (divisional de la solicitud no. 202000252) | |
BR112018068189A2 (pt) | proteínas de ligação induzíveis e métodos de uso | |
BR112018011073A2 (pt) | anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes e métodos de utilização | |
PE20211272A1 (es) | POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO | |
BR112012009854B8 (pt) | proteína de ligação de antígeno isolada recombinante que liga il-23, composição farmacêutica, molécula de ácido nucleico isolada recombinante, vetor recombinante, método de confecção da referida proteína de ligação e uso da mesma | |
BR112017014615A2 (pt) | proteínas de fusão de multi-direcionamento e seus usos | |
CL2013003634A1 (es) | Complejo que comprende una proteina de fusion que comprende, un peptido viral, peptido conector, microglobulina beta 2 , peptido conector, dominios extracelulares alfa 1, 2 y 3 de mhc de clase i y un tercer peptido conector; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso | |
BR112017008525A2 (pt) | proteína de fusão isolada, e, métodos para tratamento ou alívio de um sintoma de uma doença ou distúrbio, para tratamento ou alívio de uma inflamação ou um sintoma de uma doença ou distúrbio inflamatório e para redução do risco de infecção em um indivíduo. | |
BR112012006501A8 (pt) | Polipeptídios e usos dos mesmos | |
BR112016000565A2 (pt) | polipeptídeo cíclico, derivado ou análogo do mesmo e seu uso modulador alostérico, composição farmacêutica, processo para produzir a mesma | |
BR112017006598A2 (pt) | anticorpo de repetições antidipeptídeo derivado de ser humano (dprs) | |
BR112017028331A2 (pt) | proteínas de fusão que se ligam a receptores fc humanos | |
BR112016027595A8 (pt) | produtos de peptídeos, composição farmacêutica compreendendo um produto de peptídeo, uso de um produto de peptídeo e método para produzir um produto de peptídeo | |
PH12020550927A1 (en) | Therapeutic enzyme fusion protein having novel structure and use thereof | |
BR112016008055A2 (pt) | Proteínas com usos diagnósticos e terapêuticos | |
BR112017018538A2 (pt) | vetores de expressão eucariótica que compreendem elementos regulatórios dos clusters de gene da globina | |
BR112017022076A2 (pt) | fusões de mesotelina-variante iii de receptor de fator de crescimento epidérmico e métodos de uso das mesmas | |
BR112017011457A2 (pt) | métodos e composições relacionados a polipeptídeos funcionais incorporados em suportes de proteína heteróloga | |
BR112019010034A2 (pt) | fator viii alvejado de hemácia e método de uso do mesmo | |
ECSP22019177A (es) | Proteínas de fusión nkg2d y sus usos | |
AR095387A1 (es) | Proteínas específicas para el baff y para la b7rp1 y sus usos | |
BR112016005899A8 (pt) | composições compreendendo populações heterogêneas de proteínas de fator xa de coagulação recombinante humano, seus usos e método de purificação de uma proteína variante de fator xa. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2680 DE 17-05-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |